Twist Bioscience Corp美股招股说明书(2026-08-05版)

Common Stock Twist Bioscience Corporation is offering 3,125,000 shares of its common stock. Our common stock is listed and trades on the Nasdaq Global Select Market under the symbol“TWST.” On August4, 2026, the last reported sale price on Nasdaq of our common stock on the NasdaqGlobal Select Market was $99.44 per share. Investing in our common stock involves risks. See the section titled “Risk Factors”beginning on pageS-7of this prospectus supplement, as well as in the accompanyingprospectus and the documents incorporated by reference into this prospectus supplement andthe accompanying prospectus. Neither the Securities and Exchange Commission nor any state securities commission hasapproved or disapproved of these securities or determined if this prospectus supplement or theaccompanying prospectus is truthful or complete. Any representation to the contrary is a criminaloffense. (1)See the section titled “Underwriting” for a description of the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30days to purchase up to 468,750additional shares of our common stock at the public offering price less underwriting discounts andcommissions. The underwriters expect to deliver the shares against payment in New York, New York on or aboutAugust6, 2026. Goldman Sachs & Co. LLCWilliam BlairLeerink PartnersGuggenheim Securities Prospectus Supplement dated August4, 2026 TABLE OF CONTENTS Prospectus Supplement PageABOUT THIS PROSPECTUS SUPPLEMENTS-1PROSPECTUS SUMMARYS-3THE OFFERINGS-5RISK FACTORSS-7CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTSS-10USE OF PROCEEDSS-12DILUTIONS-13DIVIDEND POLICYS-15MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERSS-16UNDERWRITINGS-20LEGAL MATTERSS-29EXPERTSS-29WHERE YOU CAN FIND MORE INFORMATIONS-29INCORPORATION OF CERTAIN INFORMATION BY REFERENCES-30 Prospectus PageABOUT THIS PROSPECTUS1PROSPECTUS SUMMARY2RISK FACTORS4CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS5USE OF PROCEEDS7SELLING SECURITYHOLDERS8DESCRIPTION OF OUR CAPITAL STOCK9DESCRIPTION OF OUR DEBT SECURITIES12DESCRIPTION OF OUR WARRANTS13DESCRIPTION OF OUR UNITS14PLAN OF DISTRIBUTION15LEGAL MATTERS17EXPERTS17WHERE YOU CAN FIND ADDITIONAL INFORMATION17INCORPORATION OF CERTAIN INFORMATION BY REFERENCE18 ABOUT THIS PROSPECTUS SUPPLEMENT This document is in two parts. The first part is this prospectus supplement, which describes thespecific terms of this offering of shares of our common stock and also adds to and updates informationcontained in the accompanying base prospectus and the documents incorporated by reference into thisprospectus supplement and the accompanying base prospectus. The second part, the accompanyingbase prospectus, gives more general information, some of which may not apply to this offering. Youshould read both this prospectus supplement and the accompanying base prospectus before deciding toinvest in our common stock. In this prospectus supplement and the accompanying prospectus, as permitted by law, we“incorporate by reference” information from other documents that we file with the Securities andExchange Commission (the “SEC”). This means that we can disclose important information to you byreferring you to those documents. The information incorporated by reference is considered to be a part ofthis prospectus supplement and the accompanying prospectus and should be read with the same care.When we update the information contained in documents that have been incorporated by reference bymaking future filings with the SEC, the information incorporated by reference in this prospectussupplement and the accompanying prospectus is considered to be automatically updated andsuperseded. In other words, in case of a conflict or inconsistency between information contained in thisprospectus supplement and the accompanying prospectus and information incorporated by reference intothis prospectus supplement and the accompanying prospectus, you should rely on the informationcontained in the document that was filed most recently with the SEC. Neither we nor the underwriters have authorized any other person to provide you with anyinformation other than that contained or incorporated by reference into this prospectus supplement, theaccompanying prospectus or any relevant free writing prospectus prepared by or on behalf of us or towhich we have referred you. We and the underwriters take no responsibility for, and can provide noassurance as to the reliability of, any other information that others may give you. We are offering to sell,and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales arepermitted. The distribution of this prospectus supplement and the offering of the common stock in certainjurisdictions may be restricted by law. Persons outside the United States who come into possession ofthis prospectus supplement must inform themselves about, and observe any restrictions relati